Acadia Pharma (ACAD) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
RBC Capital on Acadia Pharmaceuticals (ACAD): 'We see a -1-2% stock move off the Nuplazid slight miss for 1Q23'
May 8, 2023 4:39 PM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Potential stock impact & bottom line: We see a -1-2% stock move off the Nuplazid slight miss for 1Q23, reiterated FY23 revenue guidance, offset by optimism around Daybue launch... More
